| 6NOV: reference: Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease., Benschop RJ, Chow CK, Tian Y, Nelson J, Barmettler B, Atwell S, Clawson D, Chai Q, Jones B, Fitchett J, Torgerson S, Ji Y, Bina H, Hu N, Ghanem M, Manetta J, Wroblewski VJ, Lu J, Allan BW, MAbs. 2019 Jun 10:1-16. doi: 10.1080/19420862.2019.1624463. PMID: 31181988 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).